Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

• Status: Unknown status
• Trial end date: 2018-12-15
• Target enrollment: 0
• Participant gender: All

Summary

Escitalopram has been approved by FDA in the treatment of adolescents with major depressive disorder since March 2009. To date, there are only 3 clinical trials assessing the effect and validity of escitalopram on major depressive disorder, which of them has resulted in inconsistent findings. In the present study, the authors aimed to assess the effect and validity of this drug in the treatment of adolescents with major depressive disorder and or anxiety disorders.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erzurum Regional Training & Research Hospital
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• drug-naive

• being in the age range of 12-18

• lack of any psychiatric comorbidity, except for ADHD-like problems during the illness

• IQ level> 80

• lack of history of any major medical disease, substance abuse

Exclusion Criteria:

• inappropriate age

• history of drug abuse, major medical disease

• mental retardation

• any psychotropic drug use

• hospitalization required for suicidal ideation/behavior